

**MEETING MINUTES  
OF THE  
CENTERS FOR MEDICARE AND MEDICAID SERVICES  
MEDICARE EVIDENCE DEVELOPMENT & COVERAGE  
ADVISORY COMMITTEE**

**April 30, 2014**

**Centers for Medicare and Medicaid Services  
7500 Security Boulevard  
Baltimore, Maryland**

**Medicare Evidence Development & Coverage Advisory Committee**

**April 30, 2014**

**Attendees**

**Chairperson**

Rita Redberg, MD, MS

**Vice-Chair**

Art Sedrakyan, MD, PhD

**Voting Members**

Harry Burke, MD, PhD

Allan M. Fendrick, MD, PhD

Mark D. Grant, MD, PhD

Jo Carol Hiatt, MD, MBA, FACS

David Howard, PhD

Gail Melkus, EdD, C-NP, FAAN

Curtis Mock, MD, MBA

Gerald A. White, Jr., MS, FAAPM, FACR

**CMS Liaison**

Tamara Syrek Jensen, JD

**Industry Representative**

Martin D. Marciniak, MPP, PhD

**Guest Panel Members**

V. Paul Doria-Rose, DVM, PhD

Michael K. Gould, MD, MS

Jeffrey B. Rich, MD

Steven H. Woolf, MD, MPH

**Invited Guest Speakers**

Laura Fenton Ambrose

Peter Bach, MD, MAPP

Doug Campos-Outcalt, MD, MPA

Paul Pinsky, MD

**Executive Secretary**

Maria Ellis

**Wednesday, April 30, 2014, 8:11 a.m.**

The Medicare Evidence Development & Coverage Advisory Committee met on April 30, 2014, to discuss the evidence, hear presentations and public comments, and make recommendations concerning the use of low-dose computed tomography (LDCT) screening for lung cancer in adult smokers.

The meeting began with a reading of a conflict of interest statement, welcoming remarks, and an introduction of the Committee.

**CMS Presentation and Voting Questions.** A CMS representative presented a basic background of lung cancer screening, and how Medicare's consideration of preventive services is statutorily different than evaluation and management services, and then read the voting and discussion questions that would be considered by the panel.

**Presentations by Invited Guest Speakers.** The panel heard presentations from the four invited guest speakers. Dr. Pinsky went into some detail concerning the design of the National Lung Screening Trial (NLST), and emphasized some points related to dissemination of the screening into the population setting. Dr. Bach urged Medicare coverage of LDCT screening for lung cancer, with qualifying provisions; his presentation extrapolated some of the evidence from the NLST, and addressed issues of off-label use of CT scans, effects on unstudied groups, and harms minimization and individualized decision making in the context of large risk variation. Ms. Ambrose presented the views of the Lung Cancer Alliance in support of coverage for LDCT. Dr. Campos-Outcalt presented the position and recommendations of the American Academy of Family Physicians, specifically the AAFP concerns with the USPSTF recommendation regarding LDCT for lung cancer screening including that the risks were not adequately described and they favored an I recommendation.

**Scheduled Public Comments.** The panel heard from a total of 16 scheduled speakers, including representatives from professional societies, practitioners from both community practice and academic institutions, a principal investigator from the NLST, a medical director for a CT equipment manufacturer, and an actuary.

**Open Public Comments.** The panel heard from four members of the public, including a lung cancer screening advocate and widow of a lung cancer victim, a former head of the NLST, and two representatives of the Lung Cancer Alliance.


**Questions to Presenters.** The panel participated in a lengthy discussion and question and answer session with all of the presenters.

**Initial Open Panel Discussion, Formal Remarks and Voting Questions.** The panel turned its attention to the voting questions, conducting a discussion among the panelists before voting. The results of the voting were recorded on electronic devices and recorded manually, announced to the public, and were recorded by CMS staff. Following each

voting question, the panelists focused on the discussion questions, comments on which are found in the transcript.


**Adjournment.** The meeting adjourned at 3:11 p.m.

I certify that I attended the meeting  
of the Medicare Evidence Development  
& Coverage Advisory Committee on  
April 30, 2014, and that these minutes  
accurately reflect what transpired.



\_\_\_\_\_  
Maria A. Ellis  
Executive Secretary, MEDCAC, CMS

I approve the minutes of this meeting  
as recorded in this summary.

  
\_\_\_\_\_  
Rita Redberg, MD, MS  
Chairperson